EP Patent

EP3383392B1 — Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Assigned to Global Blood Therapeutics Inc · Expires 2025-07-09 · 1y expired

What this patent protects

Patent listed against Oxbryta.

Drugs covered by this patent

Patent Metadata

Patent number
EP3383392B1
Jurisdiction
EP
Classification
—
Expires
2025-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Global Blood Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.